|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Andrei A. Raibekas, Principal Scientist Protein Formulation, Amgen Inc.
|
|
|
|
Dr. Mark Abbott, Principal Scientist, Respiratory and Inflammation, AstraZeneca (Tentative)
|
|
|
|
Dr. Hanne B. Rasmussen, Head of Department, Dep. of Protein Structure and Biophysics, Novo Nordisk A/S
|
|
|
|
Dr Alexandra Baer, Senior Scientist, Symphogen
|
|
|
|
Dr Matthew Baker, CSO, Antitope Ltd
|
|
|
|
Dr. Lucia Banci, Professor of Chemistry, Magnetic Resonance Center and Department of Chemistry, University of Florence
|
|
|
|
Dr Amrik Basran, Director, Discovery Biosciences, Biopharm CEDD, Domantis
|
|
|
|
Dr Peter Buckel, Chief Executive Officer, Suppremol GmbH, Germany
|
|
|
|
Konrad Bussow, Team Leader Helmholtz Centre for Infection Research
|
|
|
|
Laurent Chevalet, Head, Protein Biochemistry Department, Merck Serono
|
|
|
|
Dr Hans-Jürgen Christian, Head of Process Development, Pieris AG
|
|
|
|
Dr. Ciaran Cronin, Head, Group Parallel Protein Production, Structural Biology, Pfizer, Inc
|
|
|
|
Anne De Groot, CEO & President Epivax Ltd
|
|
|
|
Dr Niek Dekker, Head, Protein Biochemistry Department, Associate Director, Protein Engineering, Global Structural Chemistry
|
|
|
|
Michael Dyson, Senior Research Associate, Department of Biochemistry, University of Cambridge
|
|
|
|
Dr Georg Feger, Worldwide Head of Protein & Cell Science, Merck Serono
|
|
|
|
Dr Stephan Fischer, Senior Vice President, Biologics Research and Strategy, Roche Pharma Research, Germany
|
|
|
|
Prof. Göran Forsberg, VP Communication & Business Development, Active Biotech AB
|
|
|
|
Dr Bernd Gehartz, Unit Head, Director, Novartis
|
|
|
|
Prof. Chris Gregory, CSO ImmunoSolv Limited
|
|
|
|
Dr. Stephanie A. Harden, Biopharmaceutical Marketing Manager, Europe & India Waters
|
|
|
|
Prof. Udo Heinemann, Head of Protein Sample Production Facility, Max Delbrueck Center for Molecular Medicine, Berlin, Germany
|
|
|
|
Dr. Hanjo Hennemann, CEO Nexigen GmbH
|
|
|
|
Dr. Ian Hodgson, Head of Molecular Biology, ECS, Avecia Biologics
|
|
|
|
Dr Stephen Irving, Senior Principle Scientist, Structural Biology and Biophysics, Pfizer
|
|
|
|
Dr. Ulrike Korf, Scientist, German Cancer Research Centre
|
|
|
|
Dr Karol Kozak, Database Implementation, High Content Screening, RISC, Eth Zurich
|
|
|
|
Dr. Roland Leathers, Field Application Specialist, Invitrogen
|
|
|
|
Prof. Dr. Melvyn Little, Chief Scientific Officer, Affimed Therapeutics AG
|
|
|
|
Dr. Judit Nagy, Proteomics Facility Director, Institute of Biomedical Engineering, Imperial College London
|
|
|
|
Dr Fredrik Nilsson, Project Manager Biopharmaceuticals, Affibody
|
|
|
|
Dr. Andreas Popp, Group Leader Protein Production, Morphosys
|
|
|
|
Stefan Schmidt, Team Leader Protein Science, Astra Zeneca
|
|
|
|
Prof. Dr. Torsten Schoneberg, Molecular Biochemistry & Endocrinology, Institute of Biochemistry, Medical Faculty, University of Leipzig
|
|
|
|
Dr. Andre Sobczyk, Protein and Services Manager, tebu-bio
|
|
|
|
Dr. Indresh Srivastava, Acting Head of Protein Biochemistry, Novartis Vaccines and Diagnostics, Inc.
|
|
|
|
Prof. Joel L. Sussman, Pickman Prof. of Structural Biology , Department of Structural Biology, Weizmann Institute of Science
|
|
|
|
David Szymkowski, Senior Director, Biotherapeutics, Xencor
|
|
|
|
Dr. Markus Templin, Head Assay Development, Natural and Medical Science Institute, University of Tübingen
|
|
|
|
Barbara Valsasina, Senior Scientist, Biology Department Nerviano Medical Services
|
|
|
|
Dr. Thomas Waldmann, Science and Technology Applications, Sloning Biotechnology GmbH
|
|
|
|
Dr Grace Wong, CEO, ActoKine Therapeutics
|
|
|
|
|
|
|
|
Speakers
